Last €10.59 EUR
Change Today -0.221 / -2.04%
Volume 300.0
As of 5:44 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

zealand pharma a/s (22Z) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/5/15 - €12.41
52 Week Low
10/17/14 - €7.78
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZEALAND PHARMA A/S (22Z)

Related News

No related news articles were found.

zealand pharma a/s (22Z) Related Businessweek News

No Related Businessweek News Found

zealand pharma a/s (22Z) Details

Zealand Pharma A/S, a biotechnology company, discovers and develops peptide drugs in Denmark. Its lead drug includes Lyxumia (lixisenatide), a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes. The company’s product pipeline also comprise Lantus and Lyxumia, which are in Phase III clinical trials for the treatment of type 2 diabetes; and ZP2929, a once-daily dual acting glucagon/GLP-1 peptide agonist that is in Phase I clinical trial for the treatment of diabetes and/or obesity. In addition, it develops danegaptide, a dipeptide gap junction modifier in Phase II clinical study with cardioprotective properties; ZP1480, an MSH melanocortin peptide agonist in Phase IIb clinical trial for the prevention of acute kidney injury following surgery; Elsiglutide, a GLP-2 peptide receptor agonist in Phase II clinical trial for the prevention of chemotherapy induced diarrhea; and ZP1848, a GLP-2 peptide agonist that has completed Phase Ib trial for the treatment of inflammatory bowel disease. Further, the company has peptide drug programs in various stages of pre-clinical development, primarily in the fields of cardio-metabolic diseases, diabetes, and obesity. Zealand Pharma A/S has collaboration agreements with Sanofi S.A.; Boehringer Ingelheim International GmbH; Helsinn Healthcare S.A.; Abbvie Inc.; and Eli Lilly. The company was founded in 1998 and is based in Copenhagen, Denmark.

104 Employees
Last Reported Date: 11/7/14
Founded in 1998

zealand pharma a/s (22Z) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zealand pharma a/s (22Z) Key Developments

Zealand and Helsinn Announce the Advance of Elsiglutide into Phase IIB Development for the Prevention of Chemotherapy-Induced Diarrhea

Zealand Pharma A/S and Helsinn Healthcare S.A. jointly announce that Helsinn has started a Phase IIB clinical dose-finding trial of elsiglutide for the prevention of chemotherapy-induced diarrhea (CID). The first patients out of a planned total of 600 patients with colorectal cancer treated with chemotherapy have been dosed in the trial. Elsiglutide is a novel GLP-2 peptide receptor agonist invented by Zealand. Global development and commercial rights to elsiglutide for its use in cancer supportive care outside the Nordic countries are licensed to Helsinn. Many cancer patients who receive chemotherapy, in particular 5-fluorouracil (5-FU)-based regimens such as FOLFOX and FOLFIRI, suffer from severe diarrhea induced by damage to their intestines caused by the chemotherapy. The condition can lead to dehydration, hospitalization, sub-optimal cancer treatment and markedly reduced quality-of-life for the patients. 5-FU based chemotherapy regimens are used in particular to treat colorectal, head and neck as well as breast cancers. In Phase I and Phase IIA clinical trials, elsiglutide demonstrated favorable results in the prevention of diarrhea in colorectal cancer patients receiving chemotherapy and a good safety profile. In pre-clinical studies, elsiglutide has been shown to consistently stimulate growth of the small intestinal mucosa and decrease the incidence and severity of CID, in addition to improving bowel function, which supports its potential use in the treatment of gastro-intestinal disorders. Currently, no effective treatment exists for CID.

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S (Zealand) announced that Florian Reinaud, independent Board member and Chairman of the Remuneration Committee, will step down from the Board with effect as of February 2, 2015. This change is in line with Zealand’s previously communicated Board transition plans. Florian Reinaud, who is partner at Innovation Capital, France has served on Zealand’s Board of Directors since 2010. New Chairman of the Remuneration Committee will be Daniel J. Ellens.

Zealand Pharma A/S Raises DKK 300 Million in Royalty Bond Financing

Zealand Pharma A/S announced that the company has raised USD 50 million/DKK 300 million in a non-dilutive, non-recourse bond structured financing backed by stand-alone lixisenatide (Lyxumia(r)) royalties. The Financing is provided by Athyrium Capital Management and its funds, a U.S.-based specialist healthcare investment manager. Credit Suisse acted as sole structuring advisor and placement agent in the transaction. The royalty bond carries an interest rate of 9.375% annually, and the combined annual payments of interest and principal are limited in recourse to 86.5% of Zealand's future annual revenue on lixisenatide as stand-alone product under its license agreement with Sanofi, until the bond is repaid in full. Potential future royalty revenue on LixiLan is not part of the Financing.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
22Z:GR €10.59 EUR -0.221

22Z Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 22Z.
View Industry Companies

Industry Analysis


Industry Average

Valuation 22Z Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.9x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZEALAND PHARMA A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at